1. Home
  2. RIGL vs OPRT Comparison

RIGL vs OPRT Comparison

Compare RIGL & OPRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • OPRT
  • Stock Information
  • Founded
  • RIGL 1996
  • OPRT 2005
  • Country
  • RIGL United States
  • OPRT United States
  • Employees
  • RIGL N/A
  • OPRT N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • OPRT Finance: Consumer Services
  • Sector
  • RIGL Health Care
  • OPRT Finance
  • Exchange
  • RIGL Nasdaq
  • OPRT Nasdaq
  • Market Cap
  • RIGL 335.5M
  • OPRT 298.8M
  • IPO Year
  • RIGL 2000
  • OPRT 2019
  • Fundamental
  • Price
  • RIGL $41.50
  • OPRT $6.00
  • Analyst Decision
  • RIGL Buy
  • OPRT Hold
  • Analyst Count
  • RIGL 5
  • OPRT 2
  • Target Price
  • RIGL $38.20
  • OPRT $8.00
  • AVG Volume (30 Days)
  • RIGL 845.0K
  • OPRT 524.6K
  • Earning Date
  • RIGL 08-05-2025
  • OPRT 08-06-2025
  • Dividend Yield
  • RIGL N/A
  • OPRT N/A
  • EPS Growth
  • RIGL N/A
  • OPRT N/A
  • EPS
  • RIGL 5.43
  • OPRT N/A
  • Revenue
  • RIGL $267,921,000.00
  • OPRT $724,757,000.00
  • Revenue This Year
  • RIGL $14.41
  • OPRT $28.27
  • Revenue Next Year
  • RIGL $15.97
  • OPRT $6.59
  • P/E Ratio
  • RIGL $7.64
  • OPRT N/A
  • Revenue Growth
  • RIGL 105.62
  • OPRT N/A
  • 52 Week Low
  • RIGL $12.00
  • OPRT $2.37
  • 52 Week High
  • RIGL $43.72
  • OPRT $9.25
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 86.20
  • OPRT 46.78
  • Support Level
  • RIGL $38.43
  • OPRT $5.51
  • Resistance Level
  • RIGL $41.25
  • OPRT $6.30
  • Average True Range (ATR)
  • RIGL 2.50
  • OPRT 0.34
  • MACD
  • RIGL 0.89
  • OPRT 0.00
  • Stochastic Oscillator
  • RIGL 89.85
  • OPRT 36.11

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About OPRT Oportun Financial Corporation

Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.

Share on Social Networks: